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Abstract
Background: Patient-derived xenografts (PDX) mice models play an important role in preclinical trials and personalized medicine. Sharing data on the models is highly valuable for numerous reasons – ethical, economical, research
cross validation etc. The EurOPDX Consortium was established 8 years ago to share such information and avoid duplicating efforts in developing new PDX mice models and unify approaches to support preclinical research. EurOPDX
Data Portal is the unified data sharing platform adopted by the Consortium.
Main body: In this paper we describe the main features of the EurOPDX Data Portal (https://dataportal.europdx.eu/),
its architecture and possible utilization by researchers who look for PDX mice models for their research. The Portal
offers a catalogue of European models accessible on a cooperative basis. The models are searchable by metadata,
and a detailed view provides molecular profiles (gene expression, mutation, copy number alteration) and treatment
studies. The Portal displays the data in multiple tools (PDX Finder, cBioPortal, and GenomeCruzer in future), which are
populated from a common database displaying strictly mutually consistent views.
(Short) Conclusion: EurOPDX Data Portal is an entry point to the EurOPDX Research Infrastructure offering PDX mice
models for collaborative research, (meta)data describing their features and deep molecular data analysis according to
users’ interests.
Keywords: PDX, Molecular data analysis, Data harmonization, Research infrastructure, Database
Background
Patient-derived xenografts (PDX) become increasingly
important as they provide a new approach for preclinical
cancer research. PDX are in vivo models in which human
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cancer tissues are implanted in animal hosts, typically
immunocompromised mice [1]. Exploration of cancer
molecular features and drug response in PDX models
has yielded a huge amount of information, in some cases
leading to changes in cancer patient management [2, 3].
Since the number of researchers working with PDX
mice models across Europe is rising quickly, as well as
the number of models generated, there was a need to
organize information about European PDX mice models. To avoid duplication of efforts, enable extensive
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Fig. 1 EurOPDX Data Portal data flows. Four layers are described: (i) Input layer for metadata and processed molecular data provided by partners
from the consortium. These data are collected via templates and laboratory information management systems (LIMS); (ii) Data processing layer
where the data are collected, semi-automatically standardized and harmonized to be aligned with PDX Finder data services utilized in the Portal as
well; (iii) Storage layer consists of the Data Hub where the EurOPDX data are stored; (iv) Data analysis layer is then a graphical user interface enabling
(meta)data browsing and further analysis

collaboration, and to set up shared standards suitable for the PDX mice model facilities in Europe and
beyond (to allow for cross-validation studies, among
other reasons), the EurOPDX Consortium was established in 2013. Sharing biospecimens, data sets and
standardization of laboratory procedures following
high quality standards have been the main objectives
of the Consortium [2].
To fulfill these goals, EurOPDX has started building a
distributed infrastructure for PDX research providing
services to other research groups, including PDX mice
models biobanking and delivery, as well as drug efficacy testing. The first step towards construction of the
EurOPDX Research Infrastructure (RI) has been the joint
collection, harmonization and display of PDX-related
data from partners, according to existing and newly
developed standards. The work we present here is the
current status of the EurOPDX Data Portal1 which enables integrative search, browsing and exploration of more
than a thousand PDX models for preclinical, clinical and
molecular information.

1

https://dataportal.europdx.eu/

Construction and content
Main features of the EurOPDX Data Portal

Through its Data Portal, the EurOPDX Consortium provides access to three main types of PDX-related data:
(i) metadata, i.e., all annotations related to PDX model
construction, tumor of origin, preclinical and clinical
features as specified in the PDX-Minimal Information
(PDX-MI) standard [4], (ii) processed molecular data,
including cytogenetics and gene expression, mutation
and copy number alterations, (iii) additional data, such as
model’s drug dosing and patient treatment data.
Figure 1 illustrates the data flow, from partners owning and providing the models and related data, to the end
user of the Portal, through the Data Platform.
The current data loading process is semi-automatic
and occurs through four main steps: (i) EurOPDX data
providers fill in a metadata template. (ii) The data is
checked for consistency and harmonized (e.g., unifying the gene symbols, diagnoses identifiers etc.) before
ingesting into the database. Any additional datasets
such as processed molecular data or drug dosing studies are collected in separate files. (iii) Metadata template and datasets are processed and validated by
loader components developed within the PDX Finder
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Table 1 Overview of EurOPDX partners providing the data sets, cancer types and number of PDX mice models represented by these
data sets
Institute (acronym)

Cancer Type (data set acronym)

Number
of PDX
Models

Candiolo Cancer Institute, FPO-IRCCS (IRCC), Italy

Colorectal Cancer (IRCC-CRC)

639

Candiolo Cancer Institute, FPO-IRCCS (IRCC), Italy

Gastric Cancer (IRCC-GC)

76

Cancer Research UK, University of Cambridge, UK

Breast Cancer (UOC-BC)

59

Curie Institute - Preclinical Investigation Laboratory, France

Breast Cancer (Curie-BC)

5

Curie Institute - Preclinical Investigation Laboratory, France

Lung Cancer (Curie-LC)

6

Curie Institute - Preclinical Investigation Laboratory, France

Ovarian Cancer (Curie-OV)

5

Luxembourg Institute of Health - NORLUX laboratory

Glioma (LIH)

40

Netherlands Cancer Institute

Breast Cancer (NKI)

7

TRACE - Patient Derived Tumor Xenograft Platform, KU Leuven and UZ Leuven,
Belgium

Breast Cancer, Cutaneous Melanoma, Uterine Cancer
(TRACE)

31

Vall d’Hebron Institute of Oncology, Spain

Breast Cancer (VHIO-BC)

5

Vall d’Hebron Institute of Oncology, Spain

Colorectal Cancer (VHIO-CRC)

74

Vall d’Hebron Institute of Oncology, Spain

Pancreatic Cancer (VHIO-PC)

43

University of Manchester, UK

Breast Cancer (UOM-BC)

12

University Medical Center Groningen, Netherlands

Ovarian Cancer (UMCG)

8

catalogue [5], (iv) and uploaded into the EurOPDX
Data Hub. Details on the whole process are given in the
following sections. Technically, the same process and
software is used to populate the database of the standalone PDX Finder2 (see Fig. 1).
Currently, the Portal displays models and data for a
total of 1010 PDXs from 9 PDX providers, across seven
European Countries (Table 1).
These models represent several cancer systems listed in
Table 2.
Most of the models represent adult cancer models (93%), in 7% of cases age was not specified by the
provider.
Figure 2 shows coverage of the models by additional
data (molecular, treatment etc.). Gene mutation and copy
number alteration are already available for half of the
models or more, while other data are being introduced
gradually.
EurOPDX Data can be browsed and retrieved by the
end user through two main graphical interfaces: the Data
Portal Search Interface3 and the EurOPDX cBioPortal Interface.4 While the Search interface allows mainly
searching models by metadata, the cBioPortal interface
allows in-depth search and analysis of gene-level molecular data [6, 7], see examples at Fig. 5.

2

http://pdxfinder.org/

3

https://dataportal.europdx.eu/search

4

https://cbioportal.europdx.eu/

Input layer

Metadata is collected via Excel templates as this format
has been the most preferred based on user feedback.
The European Molecular Biology Laboratory - European
Bioinformatics Institute (EMBL-EBI) and University of
Turin teams developed and refined 9 collection templates
to ensure a global community coverage and compliance
with the PDX-MI standard [4]. This standard defines the
minimal information for describing the clinical attributes
of a patient’s tumor, the details of model creation, quality assurance methods, and metadata associated with the
model’s availability for use in cancer research. These templates have been re-used by the global PDX community
and new templates are developed or updated on an ad
hoc basis to cover new data types or attributes. Current
templates include:
Table 2 PDX models available at the EurOPDX Data Portal listed
according to cancer system
Cancer System

Number
of PDX
Models

Digestive system

842

Breast

346

Nervous system

40

Reproductive system

21

Connective and soft tissue

8

Skin

8

Thoracic

6

Dudová et al. BMC Genomics

(2022) 23:156

Page 4 of 11

Fig. 2 Visualization of data types available in the Data Portal, by percentage. Out of 1010 deposited models, 653 include gene mutation data (65%),
505 include copy number alteration data (50%), for 283 models there are available drug dosing studies (28%), 270 models include gene expression
data (27%), 103 models cytogenetics (10%), and 69 models include patient treatment data (7%)

PDX mice models and sample Metadata templates
• Basic Metadata template collecting patients’ clinical
and PDX mice models metadata
• Sample Metadata template collecting metadata for
molecular data
Individual templates for data (molecular and treatment)
• Molecular datasets templates
° Cytogenetics
° Mutation
° Copy number alterations
° Fusion
° Transcriptomic
• Treatment template (patient and PDX mice models)
° Patient treatment
° Drug Dosing of the PDX mice models
Processing layer

Metadata provided by partners are validated for adherence to the PDX-MI standard [4]. Metadata harmonization is achieved by mapping biologically identical
histological concepts provided by different sources. Specifically, to support consistent searching across resources,
we use different attributes such as original histological
term and the primary tissue provided by the resource.

For example, histological concepts “Adenosquamous”,
“adenosquamous carcinoma”, “Ad and SC carcinoma”
share the same primary tissue “lung” and are mapped
to the National Cancer Institute thesaurus (NCIt) [8]
ontological label “Adenosquamous Lung Carcinoma”.
Moreover, concepts are aggregated based on meaningful
groupings like cancer by anatomical system or cell morphology. This approach allows a search for “lung cancer”
models to display hits across all subclasses of lung cancer
models in a single query.
Processed Molecular Data Sets are retrieved by the
EMBL-EBI team from existing repositories/locations as
provided by the data owners. Data is then validated and
uploaded to a Neo4J database (details in the following
section). To populate the database a bespoke Java Extraction-Transformation-Loading (ETL) pipeline was written
to extract relevant attributes corresponding to the PDXMI standard from the data provided by the PDX mice
models providers. Software is freely available on GitHub5
under an Apache 2.0 license.6
A major bottleneck to molecular data integration is
the heterogeneity of the data produced from multiple
sources that involves a variety of sequencing platforms,
laboratory protocols and analyses. This heterogeneity
introduces strong technological biases and causes data
inconsistencies, hindering data integration efforts. To
control this technical variability, we have developed a service to remap all PDX mutation data to the same genome
5

https://github.com/pdxfinder

6

https://www.apache.org/licenses/LICENSE-2.0
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Fig. 3 EurOPDX Data Hub schema. The Hub includes the Neo4J database containing data accessible via the Data Portal Search page, and the
MySQL database providing temporary operational data. There is a REST API available within the Hub accessible to the chaining tools

assembly (GRCh38). We then re-annotated variants on a
single annotator (Variant Effect Predictor – VEP7). This
harmonization provides accurate and standardized annotation of variants, following Human Genome Variation
Society (HGVS) standards,8 and it ensures consistent
searching and linking to cancer annotation databases like
CivicDB [9], OpenCravat [10], and COSMIC [11].
In addition to the PDX-MI standard, data from the
models in the EurOPDX Data Portal comply with other
nomenclature and metadata standards accepted by the
community: NCI thesaurus [8] for cancer type, diagnosis and other cancer attributes, Human Genome Organization Gene Nomenclature Committee [12] standards
for the names and symbols of the human genes, and
International Committee on Standardized Genetic
Nomenclature for Mice [13] for host mouse strain
nomenclature. NCIt [8], ChEBI [14], CHEMBL [15] and
PubChem [16] are used to standardize drugs and compound names.
Storage layer

The EurOPDX Data Hub constitutes the repository layer
of the RI and provides an application programming interface (API) for exporting selected data sets to chaining
tools like cBioPortal, see Fig. 3.
The Data Hub is designed to handle multiple types of
datasets and databases. Three types of data are stored:
1. Clinical data that contain pseudonymized information about patients (e.g., age at the collection, sex,
diagnosis) and about PDX mice models (stage of cancer, site of the tumor, primary/metastasis status).

2. Metadata which describe how and where the PDX
mice models were created/prepared (e.g., implant site
of engraftment, an identifier of the mouse).
3. Genomic data – this comprises an enormous set of
different data types. Currently expression, copy number alteration, and mutation.
The storage is based on a Neo4J database (DB) that
follows the structure from PDX Finder’s [5] Neo4J DB
records of EurOPDX partners/data providers (the N4J
DB schema is shown in Fig. 4) models, patients, clinical data, and molecular data. Besides Neo4J there is a
MySQL DB for storing temporary data in Data Hub, and
eventual extensions not covered by the PDX Finder data
schema (it is not required currently but it was the case of
the previous version before gene expression data became
supported by PDX Finder).
Data loading tools of PDX Finder – including automatized standardization and harmonization – are used for
loading data to the shared database of the Hub. The Hub
design is not restricted to using the Neo4J database only.
On the contrary, the previous versions complemented it
with a relational database to store additional data, being
populated with other tools. The current setup is the
result of unification developments.
The RESTful API9 of the Hub provides a unified way
for export of clinical data, metadata and molecular data
for a specified set of PDX models. This API is designed
to be complete in the sense that any chained visualization
on data processing tool (cBioPortal currently, GenomeCruzer10 foreseen) can retrieve all data it needs via this
API. In this way, strict consistency of the data among the
tools is ensured. Technically, we manage the tool integration by wrapper scripts, which retrieve the data using the

7

https://www.ensembl.org/info/docs/tools/vep/index.html

9

8

https://varnomen.hgvs.org

10

https://app.swaggerhub.com/apis-docs/RadimPesa/datahub/v1

http://www.genomecruzer.com/
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Fig. 4 Schema of the Neo4J Database. Each node of the graph database schema is an entity or event captured in the data. Arrows, so called edges,
show the relationships between the nodes

API, format them appropriately, and feed to the wrapped
tools.
The Data Hub API is based on Python’s Flask framework. To ensure automated deployment and effective
maintenance, the Data Hub runs with its components
(Neo4J, MySQL, API and Proxy) within Docker containers managed by docker-compose [17].

The same data are available by the EurOPDX cBioPortal
interface, populated by a setup procedure which calls the
Data Hub API as described above. This interface is focused
on more complex analyses and visualizations of the molecular data (gene expression charts, mutations, and their
correlations), see Fig. 5 for several examples of the visualization tools available within the cBioPortal platform.

Output layer

User registration and authentication

The user interface of the above-described database is
integrated with EurOPDX Data Portal web pages in
Umbraco Content Management System [18]. The principal entry point11 is based on branded PDX Finder software with minor extensions (classifying models by their
availability for Trans-national access via the EurOPDX
RI, search by specific model identifiers, etc.). This interface allows search and selection of the models by metadata (origin, diagnosis, treatment, etc.). An example of
the search screen is shown in Fig. 6.

The Portal is freely accessible to any researcher from
the internet after a lightweight, self-service registration,
required for maintaining minimalistic records of the service usage enforced by policies of the underlying cloud
service provider, as well as to keep track of users’ agreement to the terms of Acceptable Use Policy (which is,
besides forbidding unlawful use, mostly informative only,
not restricting the use of data for non-commercial purposes), and to offer personalized services eventually. We
adopted the technical solution developed in the ELIXIR
research infrastructure [19], which merges the possibility

11

https://dataportal.europdx.eu/search
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Fig. 5 EurOPDX data visualization in the EurOPDX cBioPortal instance. A Example of plots which can be designed according to the user’s needs.
This is a plot showing EGFR gene mutations compared with age of the patient within a selected study; B OncoPrint of queried genes. Provides
information about number of samples per patient within a selected study, data types availability per each sample and gene mutations or
alterations; C Example of mutation analysis of a chosen dataset – MutationMapper tool. It is possible to browse mutations within the selected
gene - mutations mapping on a linear protein and its domains, type of the mutation – and get detailed sample information in which mutations are
present. 3D visualizations of the protein interactions and other mutation information is available by linking external databases

to use the user identity of any institution supporting the
eduGAIN12 federation, as well as social identities (Google,
LinkedIn, ORCID); migration to the emerging European
Life-Science authentication infrastructure is foreseen.

Utility and discussion
User interface

Users can reach the EurOPDX Data Portal homepage
at https://dataportal.europdx.eu/. This page displays
information about competitive calls by the EurOPDX RI
for access to PDX models, model data availability and a
link to the Search page at https://dataportal.europdx.eu/
search.
User registration/login is required to access the Search
page.
As Shown in Fig. 6, the Search page is subdivided into
two sections. On the left, multiple filters allow selection
of models by basic features, molecular data, treatment
12

https://edugain.org

data, and patient/tumor data. Each filter category is further subdivided into sub-categories, and the filters can
be mixed for accurate queries based on the user’s needs.
For users interested in accessing models through the
EurOPDX RI, a filter enables selection of models available for Trans-national access.13 Models are also accessible
on a collaborative basis, by contacting the PDX owners.
The right part of the Search page displays the results of
the query in tabular format, with each model in a separate
row. Key features of the models are presented in columns
and include model identifier (ID) and its original provider,
tumor histological classification, site of primary tumor,
collection site, and links to available datasets (Table 3).
Users can navigate to a model/patient/tumor page
or to the data of interest by clicking on the unique PDX
Model ID or data links in each row. At the lower-right
corner of the page, users find options to download search
results in a tabular format or to export them to a dedicated instance of cBioPortal for Cancer Genomics [6, 7]
13

https://www.europdx.eu/europdxri-ta
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Fig. 6 Screenshot of the Search page from the EurOPDX Data Portal

for deeper investigation of available molecular data, as
described in the next section. A pre-compiled instance
of the EurOPDX cBioPortal, including all main datasets
currently stored in the Hub is publicly available at https://
cbioportal.europdx.eu/.
A video tutorial containing the Portal functionalities
can be found on EurOPDX RI YouTube channel next to
other informative videos, please see https://youtu.be/
l2AfjjcfT2Y.
Tool chaining and consistent data availability

While the Data Portal allows to search and select models
and samples according to certain criteria, the cBioPortal
provides additional visualization and analysis capabilities.

To link these two services, we leveraged the thorough
design of the Data Hub API to extract a model selection
in Data Portal and create a dedicated cBioPortal populated only with the data associated to the specific models selected. In order to speed up the startup time of such
cBioPortal personalized to a user’s interest, snapshots of
partially prepared (namely populated with all static data)
cBioPortal Docker containers are reused.

Conclusions
The EurOPDX Data Portal provides essential search
functionality as well as complex molecular data analysis and visualization for cancer researchers interested in
accessing PDX mice models. In particular, the Portal is
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Table 3 Links to publicly available datasets
Institute (acronym)

Cancer Type (data set acronym) Relevant PDX Models

Curie Institute - Preclinical Investiga- Ovarian Cancer (Curie-OV)
tion Laboratory, France

Link to data

OV10, OV14

http://identifiers.org/doi:10.17632/
fstsb2xfsf.1

OV25

http://identifiers.org/doi:10.17632/
fstsb2xfsf.1; http://www.ebi.ac.uk/
biostudies/studies/S-EPMC5725143?
xr=true

OV16, OV54

http://www.ebi.ac.uk/biostudies/studi
es/S-EPMC5725143?xr=true

Luxembourg Institute of Health NORLUX laboratory

Glioma (LIH)

T16, T192, T233, T251, T341, T347,
T470, T476, T591, T384

http://identifiers.org/ebi/bioproject:
PRJNA627814

TRACE - Patient Derived Tumor
Xenograft Platform, KU Leuven and
UZ Leuven, Belgium

Breast Cancer, Cutaneous Melanoma, Uterine Cancer (TRACE)

MEL0029LY

https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE70180

MEL0002LY

https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE116237

Vall d’Hebron Institute of Oncology,
Spain

Colorectal Cancer (VHIO-CRC)

M001, M043

https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE96528

University Medical Center Groningen, Netherlands

Ovarian Cancer (UMCG)

UMCGOVPDX81, UMCGOVPDX68a,
UMCGOVPDX37, UMCGOVPDX56,
UMCGOVPDX84, UMCGOVPDX70,
UMCGOVPDX79, UMCGOVPDX36

https://www.ebi.ac.uk/biostudies/
studies/S-EPMC4594124?xr=true

the primary entry point for users interested in the freeof-charge research services offered by the EurOPDX RI.
Indeed, from the perspective of the user looking for PDX
models that are relevant to his/her research, retrieval of
this information in the Portal serves as a background to
request specific trans-national access services provided
by the EurOPDX RI -- frozen PDX tumour samples shipment, in vivo studies on the selected PDX model(s),
deposition of PDX model(s) (unlike the open access to
data in the Portal, these services may be subject to further restrictions). The Portal is populated with curated
data, special attention is paid to their thorough harmonization so that queries across multiple studies are possible. The procedure of data curation is well-defined
and automated as much as possible to both speed up
the process and avoid unintentional human errors. The
data are shared among the Portal components, making
sure by technical means that they are always mutually
consistent.
At the time of writing this article, the Portal offers
data on 1010 PDX models referring to 7 distinct cancer
types, and the number models is expected to grow steadily. As such, the Portal provides the technical prerequisites to achieve the principal missions of the EurOPDX
Consortium, which is to enable data sharing among the
partners as well as to the broader research community,
thereby improving the efficiency of PDX research and
reducing duplication of efforts and unnecessary animal
experiments.
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